Janssen LYM3003/Sparkle; A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma

The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).

Principal Investigator:
​Van Huynh, MD

Research Coordinator:
Dorian Chan
(714) 509-8646

Visit clinicaltrials.gov for more information about this trial.



  • Clinical Trial Info
  • IRB Number: 1711124
  • Sponsor: Janssen Research & Development, LLC
  • Protocol Number: LYM3003
  • NCT Number: NCT02703272
  • Research Type: Lymphoma
  • Phase: III
  • Status: Active - Open to Enrollment